Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2015 1
2021 1
2022 2
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, De Giorgi U, Andreetta C, Cinieri S, De Angelis C, Priolo D, Casanova C, Rosati M, Greco F, Zafarana E, Schiavetto I, Mammoliti S, Cecere SC, Salutari V, Scalone S, Farolfi A, Di Napoli M, Lorusso D, Gargiulo P, Califano D, Russo D, Spina A, De Cecio R, Chiodini P, Perrone F; MITO investigators. Pignata S, et al. Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14. Lancet Oncol. 2023. PMID: 37052965 Clinical Trial.
Neoadjuvant chemotherapy in cervical cancer: an update.
Lapresa M, Parma G, Portuesi R, Colombo N. Lapresa M, et al. Expert Rev Anticancer Ther. 2015;15(10):1171-81. doi: 10.1586/14737140.2015.1079777. Epub 2015 Sep 7. Expert Rev Anticancer Ther. 2015. PMID: 26402247 Review.
Myeloid neoplasms post PARP inhibitors for ovarian cancer.
Caruso G, Gigli F, Parma G, Lapresa M, Derio S, Palaia I, Colombo N. Caruso G, et al. Among authors: lapresa m. Int J Gynecol Cancer. 2023 Apr 3;33(4):598-606. doi: 10.1136/ijgc-2022-004190. Int J Gynecol Cancer. 2023. PMID: 36707087 Review.
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
Colombo N, Tomao F, Benedetti Panici P, Nicoletto MO, Tognon G, Bologna A, Lissoni AA, DeCensi A, Lapresa M, Mancari R, Palaia I, Tasca G, Tettamanzi F, Alvisi MF, Rulli E, Poli D, Carlucci L, Torri V, Fossati R, Biagioli E; BAROCCO study group. Colombo N, et al. Among authors: lapresa m. Gynecol Oncol. 2022 Mar;164(3):505-513. doi: 10.1016/j.ygyno.2022.01.015. Epub 2022 Jan 19. Gynecol Oncol. 2022. PMID: 35063281 Clinical Trial.
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.
Di Liello R, Arenare L, Raspagliesi F, Scambia G, Pisano C, Colombo N, Frezzini S, Tognon G, Artioli G, Gadducci A, Lauria R, Ferrero A, Cinieri S, De Censi A, Breda E, Scollo P, De Giorgi U, Lissoni AA, Katsaros D, Lorusso D, Salutari V, Cecere SC, Lapresa M, Nardin M, Bogani G, Distefano M, Greggi S, Gargiulo P, Schettino C, Gallo C, Daniele G, Califano D, Perrone F, Pignata S, Piccirillo MC. Di Liello R, et al. Among authors: lapresa m. Int J Gynecol Cancer. 2021 Oct;31(10):1348-1355. doi: 10.1136/ijgc-2021-002786. Epub 2021 Aug 30. Int J Gynecol Cancer. 2021. PMID: 34462317 Clinical Trial.
Dose-dense neoadjuvant chemotherapy before radical surgery in cervical cancer: a retrospective cohort study and systematic literature review.
Caruso G, Bruni S, Lapresa M, De Vitis LA, Parma G, Minicucci V, Betella I, Schivardi G, Peccatori F, Lazzari R, Cliby W, Aletti GD, Zanagnolo V, Maggioni A, Colombo N, Multinu F. Caruso G, et al. Among authors: lapresa m. Int J Gynecol Cancer. 2023 Nov 10:ijgc-2023-004928. doi: 10.1136/ijgc-2023-004928. Online ahead of print. Int J Gynecol Cancer. 2023. PMID: 37949488
A Ten-Year Real-Life Experience with Pazopanib in Uterine Leyomiosarcoma in Two High-Specialized Centers in Italy: Effectiveness and Safety.
Mantiero M, Bini M, Polignano M, Porcu L, Sanfilippo R, Fabbroni C, Parma G, Lapresa M, Calidona C, Silvestri C, Franza A, Raspagliesi F, Colombo N, Ducceschi M. Mantiero M, et al. Among authors: lapresa m. Cancers (Basel). 2023 Dec 30;16(1):192. doi: 10.3390/cancers16010192. Cancers (Basel). 2023. PMID: 38201619 Free PMC article.
Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: results of a multicenter retrospective Italian study.
Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Colombo N, Fanucchi A, Chiudinelli F, Lapresa M, Maria Ferrero A. Gadducci A, et al. Among authors: lapresa m. Gynecol Oncol. 2005 Jul;98(1):118-23. doi: 10.1016/j.ygyno.2005.04.012. Gynecol Oncol. 2005. PMID: 15913740